Durvalumab with olaparib was tested in the phase I/II MEDIOLA basket trial (NCT02734004), in patients carrying a germline BRCA mutation with various advanced solid tumors, including 34 HER2-negative metastatic BC women (16 HR+, 18 TNBC) pretreated with up to two prior lines of CT. This evidence concerns the gene ERBB2 and breast cancer.